On April 26th, the FDA announced its decision regarding several electronic cigarette products from NJOY Ace, which includes authorizing four new tobacco products through the premarket tobacco product application (PMTA) pathway. The FDA issued a marketing authorization order to NJOY LLC for their Ace closed system electronic cigarette device and three companion tobacco-flavored e-liquid pods, as follows:
NJOY Ace device.
The NJOY Ace Pod Classic Tobacco 2.4% is a tobacco-flavored vaping pod.
The NJOY Ace Pod Classic Tobacco 5 is a tobacco-flavored vape pod made by NJOY.
The NJOY Ace Pod in Rich Tobacco, containing 5% nicotine.
This authorization allows these products to be sold legally in the United States. Although this action permits the sale of these particular products in the U.S., it does not mean that they are safe or FDA-approved. All tobacco products are harmful and can be addictive. Those who do not use tobacco products should not start using them.
The US Food and Drug Administration has issued a marketing denial order to NJOY for several of its flagship electronic cigarette products. Any of these products currently on the market must be removed, or the FDA may take enforcement action. Retailers with questions regarding their inventory should contact NJOY. Applications for two mint-flavored Ace electronic liquid pods are still under FDA review.
According to the PMTA process, applicants must demonstrate to the agency that the marketing of their new tobacco products is appropriate for protecting public health, among other requirements. The authorized NJOY product is believed to meet this standard because chemical testing has shown that the overall levels of harmful and potentially harmful constituents (HPHCs) in their aerosol are lower than those found in cigarette smoke. Additionally, data provided by the applicant indicates that participants who only used the authorized NJOY Ace product were exposed to lower levels of HPHCs compared to dual users of new products and cigarettes. Therefore, these products have the potential to benefit adult smokers who completely switch or significantly reduce their cigarette consumption.
Furthermore, the FDA has considered the risks and benefits to the entire population, including both tobacco users and non-users, and most importantly, youth. This includes reviewing existing data on the potential for youth use of the product. For authorized products, the FDA believes that the potential benefits of significantly reducing or completely ceasing smoking among adult smokers outweigh the risks to youth if the company complies with post-market requirements to reduce youth exposure and marketing.
In addition, the authorization imposes strict marketing restrictions on the company to greatly reduce the possibility of youth exposure to tobacco advertisements for these products. The Food and Drug Administration will closely monitor the marketing methods of these products and will take necessary action if the company fails to comply with any applicable legal or regulatory requirements or if the number of non-smokers (including youth) using these products increases significantly.
If the FDA determines that a product is no longer "appropriate for protecting public health" to continue being sold, for example, if there is a significant increase in the number of teenagers who start smoking, the FDA may suspend or rescind marketing approval issued under the PMTA pathway for various reasons.
The FDA must edit commercial secrets and confidential commercial information (CCI) before providing marketing decision documents to the public, and ensure that the files posted on the FDA website are available for everyone to read. For these reasons, the complete summary of the marketing authorization decision may not be posted on the webpage of the pre-market tobacco product marketing authorization order until after the order is issued. During this period, in order to provide as much information as possible at the time of the order, the FDA is providing an edited version of the order letter and the "executive summary" section of the decision summary, to broadly explain the public health reasons for authorizing these products.
Source: FDA official website.
The Food and Drug Administration (FDA) has made marketing decisions regarding Njoy Ace e-cigarette products.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
